0
     

Report Added
Report already added
Vaccine Adjuvants Market by Product (Particulate, Emulsions, Pathogen, Saponin), Route of Administration (Subcutaneous, Intramuscular), Disease Type (Infectious, Cancer), Application (Research, Commercial) & Application Category - Global Forecast to 2027

Vaccine Adjuvants Market by Product (Particulate, Emulsions, Pathogen, Saponin), Route of Administration (Subcutaneous, Intramuscular), Disease Type (Infectious, Cancer), Application (Research, Commercial) & Application Category - Global Forecast to 2027

The vaccine adjuvants market is projected to reach USD 1.6 Billion by 2027 from USD 1.5 Billion in 2022, at a CAGR of 1.7% during the forecast period. The growth of the market is projected to be driven by factors such as the rising prevalence of infectious diseases, increasing number of COVID-19 vaccines in the development pipeline, and increasing focus on immunization programs.
The adjuvant emulsions accounted for the largest share of the product segment in the vaccine adjuvants market in 2021.

Adjuvant emulsions function by generating depots that can trap antigens at the injection site. This results in slow release to continue the stimulation of the immune system. The adjuvant emulsions segment accounted for the largest share of the market in 2021. The extensive use of adjuvant emulsions in COVID-19 and other infectious diseases and the rising prevalence of infectious diseases are driving the growth of the adjuvant emulsions segment during the forecast period.

The infectious disease segment accounted for the largest share of the disease type segment in the vaccine adjuvants market in 2021.

The infectious diseases segment accounted for the largest share of the market in 2021. The large share of this segment can be attributed to the increasing prevalence of infectious diseases and the rising demand for new adjuvanted vaccines.

Key players in the vaccine adjuvants market include Prominent players in the global vaccine adjuvants market are GSK plc (UK), Dynavax Technologies (US), Novavax (US), Agenus Inc. (US), Croda International plc (UK), Seppic (France), OZ Biosciences (US), Phibro Animal Health Corporation (US), Associated British Foods plc (UK), InvivoGen (US), Merck KGaA (Germany), CSL Limited (Australia), Vertellus (US), Allergy Therapeutics (UK), Riboxx GmbH (Germany), CaPtivatϵ Pharmaceuticals LLC (US), EuBiologics Co., Ltd. (South Korea), Pacific GeneTech Limited (US), Hawaii Biotech Inc. (US), and Vaxine Pty Ltd. (Australia).

“Asia Pacific: The fastest-growing region in the vaccine adjuvants market”

The Asia Pacific is estimated to be the fastest-growing segment of the market, owing to the increasing investments in the life sciences sector and rising awareness through conferences and symposiums. In this region, China and Japan are the largest markets while India is projected to grow at a highest CAGR during the forecast period.

The primary interviews conducted for this report can be categorized as follows:
•By Respondent: Supply Side- 80% and Demand Side - 20%
•By Designation: Managers- 45%, CXOs and Director level - 30%, and Executives - 25%
•By Region: North America -20%, Europe -10%, Asia-Pacific -55%, RoW -15%

List of Companies Profiled in the Report:
•GSK plc (UK)
•Dynavax Technologies (US)
•Novavax (US)
•Agenus Inc. (US)
•Croda International plc (UK)
•Seppic (France)
•OZ Biosciences (US)
•Phibro Animal Health Corporation (US)
•Associated British Foods plc (UK)
•InvivoGen (US)
•Merck KGaA (Germany)
•CSL Limited (Australia)
•Vertellus (US)
•Allergy Therapeutics (UK)
•Riboxx GmbH (Germany)
•CaPtivatϵ Pharmaceuticals LLC (US)
•EuBiologics Co., Ltd. (South Korea)
•Pacific GeneTech Limited (US)
•Hawaii Biotech Inc. (US)
•Vaxine Pty Ltd. (Australia)
•Creative Diagnostics (US)
•LiteVax BV (Netherlands)
•Mukta Industries (India)
•Oncovir, Inc. (US)
•TiterMax USA, Inc. (US).

Research Coverage:
This report provides a detailed picture of the vaccine adjuvants market. It aims at estimating the size and future growth potential of the market across different segments such as the product, functionality, formulation and region. The report also includes an in-depth competitive analysis of the key market players along with their company profiles recent developments and key market strategies.

Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall vaccine adjuvants market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, challenges, and opportunities.
Table of Contents

1INTRODUCTION30
1.1STUDY OBJECTIVES30
1.2MARKET DEFINITION30
1.2.1INCLUSIONS AND EXCLUSIONS31
1.3MARKET SCOPE31
1.3.1MARKETS COVERED31
1.3.2YEARS CONSIDERED32
1.4CURRENCY32
1.5LIMITATIONS32
1.6STAKEHOLDERS33
1.7SUMMARY OF CHANGES33
2RESEARCH METHODOLOGY35
2.1RESEARCH APPROACH35
FIGURE 1RESEARCH DESIGN35
2.1.1PRIMARY RESEARCH36
FIGURE 2VACCINE ADJUVANTS MARKET: PRIMARY RESPONDENTS36
2.2MARKET ESTIMATION METHODOLOGY37
FIGURE 3VACCINE ADJUVANTS MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 202137
FIGURE 4MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE ANALYSIS-BASED ESTIMATION), 202138
2.2.1INSIGHTS FROM PRIMARY EXPERTS39
FIGURE 5MARKET SIZE VALIDATION FROM PRIMARY SOURCES39
2.3MARKET GROWTH RATE PROJECTIONS40
FIGURE 6VACCINE ADJUVANTS MARKET (DEMAND SIDE): GROWTH ANALYSIS OF DEMAND-SIDE FACTORS41
2.4DATA TRIANGULATION42
FIGURE 7DATA TRIANGULATION METHODOLOGY42
2.5RESEARCH ASSUMPTIONS43
2.6RISK ANALYSIS43
3EXECUTIVE SUMMARY44
FIGURE 8VACCINE ADJUVANTS MARKET, BY PRODUCT, 2022 VS. 2027 (USD MILLION)44
FIGURE 9VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION,
2022 VS. 2027 (USD MILLION)45
FIGURE 10VACCINE ADJUVANTS MARKET, BY DISEASE TYPE,
2022 VS. 2027 (USD MILLION)45
FIGURE 11VACCINE ADJUVANTS MARKET, BY APPLICATION,
2022 VS. 2027 (USD MILLION)46
FIGURE 12VACCINE ADJUVANTS MARKET, BY APPLICATION CATEGORY,
2022 VS. 2027 (USD MILLION)46
FIGURE 13GEOGRAPHICAL SNAPSHOT OF VACCINE ADJUVANTS MARKET47
4PREMIUM INSIGHTS48
4.1VACCINE ADJUVANTS MARKET OVERVIEW48
FIGURE 14RISING PREVALENCE OF INFECTIOUS DISEASES TO DRIVE MARKET48
4.2NORTH AMERICA: VACCINE ADJUVANTS MARKET, BY PRODUCT AND COUNTRY (2021)49
FIGURE 15ADJUVANT EMULSIONS ACCOUNTED FOR LARGEST MARKET SHARE IN 202149
4.3VACCINE ADJUVANTS MARKET SHARE, BY PRODUCT, 2022 VS. 202750
FIGURE 16ADJUVANT EMULSIONS SEGMENT WILL CONTINUE TO DOMINATE MARKET IN 202750
4.4VACCINE ADJUVANTS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES50
FIGURE 17CHINA TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD50
5MARKET OVERVIEW51
5.1INTRODUCTION51
5.2MARKET DYNAMICS51
FIGURE 18VACCINE ADJUVANTS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES51
TABLE 1VACCINE ADJUVANTS MARKET: IMPACT ANALYSIS52
5.2.1DRIVERS52
5.2.1.1Rising prevalence of infectious diseases52
5.2.1.2Increasing use of adjuvants in vaccines53
5.2.1.3Collaborations and partnerships among market players for development of vaccine adjuvants53
5.2.1.4Increasing number of COVID-19 vaccines in development pipeline53
FIGURE 19TOP LOCATIONS BASED ON NUMBER OF COVID-19 VACCINES IN DEVELOPMENT PIPELINE (AS OF OCTOBER 2021)54
5.2.1.5Increasing focus on immunization programs54
5.2.2RESTRAINTS54
5.2.2.1Skepticism about animal-sourced vaccine adjuvants and limitations on shark fishing54
5.2.3OPPORTUNITIES55
5.2.3.1Rising funding for vaccines and infectious disease research activities55
TABLE 2NIH FUNDING FOR VACCINE RESEARCH, 2018–2022 (USD MILLION)55
5.2.3.2Development of plant-based vaccine adjuvants55
5.2.4CHALLENGES56
5.2.4.1Side effects and high toxicity of adjuvants56
5.3RANGES/SCENARIOS56
FIGURE 20SCENARIOS BASED ON IMPACT OF UNCERTAINTIES ON GROWTH OF VACCINE ADJUVANTS MARKET56
5.4TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES57
FIGURE 21REVENUE SHIFT AND NEW REVENUE POCKETS FOR VACCINE ADJUVANT PROVIDERS57
5.5PRICING ANALYSIS57
5.5.1AVERAGE SELLING PRICE OF PRODUCTS OFFERED BY MARKET PLAYERS57
TABLE 3AVERAGE SELLING PRICE OF PRODUCTS OFFERED BY MARKET PLAYERS57
5.5.2AVERAGE SELLING PRICE TREND58
5.6TECHNOLOGY ANALYSIS58
5.6.1SUPERCRITICAL FLUID EXTRACTION TECHNOLOGY58
5.7VALUE CHAIN ANALYSIS59
FIGURE 22VALUE CHAIN ANALYSIS59
5.8ECOSYSTEM ANALYSIS60
FIGURE 23ECOSYSTEM ANALYSIS60
TABLE 4SUPPLY CHAIN ECOSYSTEM60
5.9PATENT ANALYSIS61
FIGURE 24PATENT APPLICATIONS RELATED TO VACCINE ADJUVANTS MARKET, JANUARY 2012–AUGUST 202261
5.10KEY CONFERENCES AND EVENTS IN 2022–202362
TABLE 5LIST OF CONFERENCES AND EVENTS IN VACCINE ADJUVANTS MARKET62
5.11REGULATORY ANALYSIS63
5.11.1REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS IN DIFFERENT REGIONS/COUNTRIES63
5.12PORTER’S FIVE FORCES ANALYSIS64
TABLE 6PORTER’S FIVE FORCES ANALYSIS64
5.12.1THREAT OF NEW ENTRANTS64
5.12.2THREAT OF SUBSTITUTES65
5.12.3BARGAINING POWER OF BUYERS65
5.12.4BARGAINING POWER OF SUPPLIERS65
5.12.5DEGREE OF COMPETITION65
5.13KEY STAKEHOLDERS AND BUYING CRITERIA66
5.13.1KEY STAKEHOLDERS IN PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES AND THEIR INFLUENCE ON BUYING PROCESS66
FIGURE 25INFLUENCE OF STAKEHOLDERS IN PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES ON BUYING PROCESS OF VACCINE ADJUVANTS66
5.13.2BUYING CRITERIA FOR VACCINE ADJUVANTS66
FIGURE 26BUYING CRITERIA FOR VACCINE ADJUVANTS66
6VACCINE ADJUVANTS MARKET, BY PRODUCT67
6.1INTRODUCTION68
TABLE 7VACCINE ADJUVANTS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)68
6.2ADJUVANT EMULSIONS68
6.2.1ADJUVANT EMULSIONS FUNCTION BY GENERATING DEPOTS THAT TRAP ANTIGENS AT INJECTION SITE68
TABLE 8ADJUVANT EMULSIONS MARKET, BY REGION, 2020–2027 (USD MILLION)69
TABLE 9NORTH AMERICA: ADJUVANT EMULSIONS MARKET, BY COUNTRY,
2020–2027 (USD MILLION)69
TABLE 10EUROPE: ADJUVANT EMULSIONS MARKET, BY COUNTRY,
2020–2027 (USD MILLION)70
TABLE 11ASIA PACIFIC: ADJUVANT EMULSIONS MARKET, BY COUNTRY,
2020–2027 (USD MILLION)70
6.3PATHOGEN COMPONENTS70
6.3.1PROMINENT MARKET PLAYERS DEVELOPING BACTERIA-DERIVED ADJUVANTS—KEY FACTOR SUPPORTING MARKET GROWTH70
TABLE 12PATHOGEN COMPONENTS MARKET, BY REGION, 2020–2027 (USD MILLION)71
TABLE 13NORTH AMERICA: PATHOGEN COMPONENTS MARKET, BY COUNTRY,
2020–2027 (USD MILLION)71
TABLE 14EUROPE: PATHOGEN COMPONENTS MARKET, BY COUNTRY,
2020–2027 (USD MILLION)72
TABLE 15ASIA PACIFIC: PATHOGEN COMPONENTS MARKET, BY COUNTRY,
2020–2027 (USD MILLION)72
6.4SAPONIN-BASED ADJUVANTS73
6.4.1GROWING DEMAND FOR SAPONIN-BASED ADJUVANTS TO DRIVE MARKET73
TABLE 16SAPONIN-BASED ADJUVANTS MARKET, BY REGION,
2020–2027 (USD MILLION)73
TABLE 17NORTH AMERICA: SAPONIN-BASED ADJUVANTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)74
TABLE 18EUROPE: SAPONIN-BASED ADJUVANTS MARKET, BY COUNTRY,
2020–2027 (USD MILLION)74
TABLE 19ASIA PACIFIC: SAPONIN-BASED ADJUVANTS MARKET, BY COUNTRY,
2020–2027 (USD MILLION)74
6.5PARTICULATE ADJUVANTS75
6.5.1MINERAL-BASED ADJUVANTS MOST WIDELY USED AMONG PARTICULATE ADJUVANTS75
TABLE 20PARTICULATE ADJUVANTS MARKET, BY REGION, 2020–2027 (USD MILLION)75
TABLE 21NORTH AMERICA: PARTICULATE ADJUVANTS MARKET, BY COUNTRY,
2020–2027 (USD MILLION)76
TABLE 22EUROPE: PARTICULATE ADJUVANTS MARKET, BY COUNTRY,
2020–2027 (USD MILLION)76
TABLE 23ASIA PACIFIC: PARTICULATE ADJUVANTS MARKET, BY COUNTRY,
2020–2027 (USD MILLION)76
6.6OTHER ADJUVANTS77
TABLE 24OTHER VACCINE ADJUVANTS MARKET, BY REGION,
2020–2027 (USD MILLION)77
TABLE 25NORTH AMERICA: OTHER VACCINE ADJUVANTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)77
TABLE 26EUROPE: OTHER VACCINE ADJUVANTS MARKET, BY COUNTRY,
2020–2027 (USD MILLION)78
TABLE 27ASIA PACIFIC: OTHER VACCINE ADJUVANTS MARKET, BY COUNTRY,
2020–2027 (USD MILLION)78

7VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION79
7.1INTRODUCTION80
TABLE 28VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION,
2020–2027 (USD MILLION)80
7.2INTRAMUSCULAR80
7.2.1LARGEST AND FASTEST-GROWING MARKET SEGMENT80
TABLE 29ADVANTAGES AND DISADVANTAGES OF INTRAMUSCULAR ADMINISTRATION81
TABLE 30VACCINE ADJUVANTS MARKET FOR INTRAMUSCULAR ADMINISTRATION,
BY REGION, 2020–2027 (USD MILLION)81
TABLE 31NORTH AMERICA: VACCINE ADJUVANTS MARKET FOR INTRAMUSCULAR ADMINISTRATION, BY COUNTRY, 2020–2027 (USD MILLION)81
TABLE 32EUROPE: VACCINE ADJUVANTS MARKET FOR INTRAMUSCULAR ADMINISTRATION, BY COUNTRY, 2020–2027 (USD MILLION)82
TABLE 33ASIA PACIFIC: VACCINE ADJUVANTS MARKET FOR INTRAMUSCULAR ADMINISTRATION, BY COUNTRY, 2020–2027 (USD MILLION)82
7.3SUBCUTANEOUS83
7.3.1ADVANTAGES OFFERED BY SUBCUTANEOUS ADMINISTRATION TO DRIVE MARKET83
TABLE 34ADVANTAGES AND DISADVANTAGES OF SUBCUTANEOUS ADMINISTRATION83
TABLE 35VACCINE ADJUVANTS MARKET FOR SUBCUTANEOUS ADMINISTRATION,
BY REGION, 2020–2027 (USD MILLION)83
TABLE 36NORTH AMERICA: VACCINE ADJUVANTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY COUNTRY, 2020–2027 (USD MILLION)84
TABLE 37EUROPE: VACCINE ADJUVANTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY COUNTRY, 2020–2027 (USD MILLION)84
TABLE 38ASIA PACIFIC: VACCINE ADJUVANTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY COUNTRY, 2020–2027 (USD MILLION)84
7.4OTHER ROUTES OF ADMINISTRATION85
TABLE 39VACCINE ADJUVANTS MARKET FOR OTHER ROUTES OF ADMINISTRATION,
BY REGION, 2020–2027 (USD MILLION)85
TABLE 40NORTH AMERICA: VACCINE ADJUVANTS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2020–2027 (USD MILLION)85
TABLE 41EUROPE: VACCINE ADJUVANTS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2020–2027 (USD MILLION)86
TABLE 42ASIA PACIFIC: VACCINE ADJUVANTS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2020–2027 (USD MILLION)86
8VACCINE ADJUVANTS MARKET, BY DISEASE TYPE87
8.1INTRODUCTION88
TABLE 43VACCINE ADJUVANTS MARKET, BY DISEASE TYPE,
2020–2027 (USD MILLION)88
8.2INFECTIOUS DISEASES88
8.2.1INCREASED PREVALENCE OF INFECTIOUS DISEASES TO DRIVE MARKET88
TABLE 44VACCINE ADJUVANTS MARKET FOR INFECTIOUS DISEASES, BY REGION, 2020–2027 (USD MILLION)89
TABLE 45NORTH AMERICA: VACCINE ADJUVANTS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2020–2027 (USD MILLION)90
TABLE 46EUROPE: VACCINE ADJUVANTS MARKET FOR INFECTIOUS DISEASES,
BY COUNTRY, 2020–2027 (USD MILLION)90
TABLE 47ASIA PACIFIC: VACCINE ADJUVANTS MARKET FOR INFECTIOUS DISEASES,
BY COUNTRY, 2020–2027 (USD MILLION)90
8.3CANCER91
8.3.1INCREASING DEMAND FOR NOVEL CANCER VACCINES TO SUPPORT MARKET GROWTH91
TABLE 48VACCINE ADJUVANTS MARKET FOR CANCER, BY REGION,
2020–2027 (USD MILLION)91
TABLE 49NORTH AMERICA: VACCINE ADJUVANTS MARKET FOR CANCER, BY COUNTRY, 2020–2027 (USD MILLION)91
TABLE 50EUROPE: VACCINE ADJUVANTS MARKET FOR CANCER, BY COUNTRY,
2020–2027 (USD MILLION)92
TABLE 51ASIA PACIFIC: VACCINE ADJUVANTS MARKET FOR CANCER, BY COUNTRY, 2020–2027 (USD MILLION)92
8.4OTHER DISEASES93
TABLE 52VACCINE ADJUVANTS MARKET FOR OTHER DISEASES, BY REGION,
2020–2027 (USD MILLION)93
TABLE 53NORTH AMERICA: VACCINE ADJUVANTS MARKET FOR OTHER DISEASES,
BY COUNTRY, 2020–2027 (USD MILLION)93
TABLE 54EUROPE: VACCINE ADJUVANTS MARKET FOR OTHER DISEASES, BY COUNTRY, 2020–2027 (USD MILLION)94
TABLE 55ASIA PACIFIC: VACCINE ADJUVANTS MARKET FOR OTHER DISEASES,
BY COUNTRY, 2020–2027 (USD MILLION)94
9VACCINE ADJUVANTS MARKET, BY APPLICATION95
9.1INTRODUCTION96
TABLE 56VACCINE ADJUVANTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)96
9.2RESEARCH APPLICATIONS96
9.2.1EXTENSIVE R&D FOR DEVELOPMENT OF VACCINE ADJUVANTS TO DRIVE MARKET96
TABLE 57VACCINE ADJUVANTS MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)97
TABLE 58NORTH AMERICA: VACCINE ADJUVANTS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)97
TABLE 59EUROPE: VACCINE ADJUVANTS MARKET FOR RESEARCH APPLICATIONS,
BY COUNTRY, 2020–2027 (USD MILLION)98
TABLE 60ASIA PACIFIC: VACCINE ADJUVANTS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)98
9.3COMMERCIAL APPLICATIONS98
9.3.1GROWING USE OF VACCINE ADJUVANTS FOR COMMERCIAL APPLICATIONS TO SUPPORT MARKET GROWTH98
TABLE 61VACCINE ADJUVANTS MARKET FOR COMMERCIAL APPLICATIONS,
BY REGION, 2020–2027 (USD MILLION)99
TABLE 62NORTH AMERICA: VACCINE ADJUVANTS MARKET FOR COMMERCIAL APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)99
TABLE 63EUROPE: VACCINE ADJUVANTS MARKET FOR COMMERCIAL APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)100
TABLE 64ASIA PACIFIC: VACCINE ADJUVANTS MARKET FOR COMMERCIAL APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)100
10VACCINE ADJUVANTS MARKET, BY APPLICATION CATEGORY101
10.1INTRODUCTION102
TABLE 65VACCINE ADJUVANTS MARKET, BY APPLICATION CATEGORY,
2020–2027 (USD MILLION)102
10.2HUMAN VACCINE ADJUVANTS102
10.2.1INCREASE IN PARTNERSHIPS FOR DEVELOPMENT OF HUMAN VACCINE ADJUVANTS102
TABLE 66HUMAN VACCINE ADJUVANTS MARKET, BY REGION,
2020–2027 (USD MILLION)103
TABLE 67NORTH AMERICA: HUMAN VACCINE ADJUVANTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)103
TABLE 68EUROPE: HUMAN VACCINE ADJUVANTS MARKET, BY COUNTRY,
2020–2027 (USD MILLION)103
TABLE 69ASIA PACIFIC: HUMAN VACCINE ADJUVANTS MARKET, BY COUNTRY,
2020–2027 (USD MILLION)104
10.3VETERINARY VACCINE ADJUVANTS104
10.3.1DEVELOPMENT OF ANIMAL VACCINES GOVERNED BY FEWER REGULATORY ASPECTS104
TABLE 70VETERINARY VACCINE ADJUVANTS MARKET, BY REGION,
2020–2027 (USD MILLION)105
TABLE 71NORTH AMERICA: VETERINARY VACCINE ADJUVANTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)105
TABLE 72EUROPE: VETERINARY VACCINE ADJUVANTS MARKET, BY COUNTRY,
2020–2027 (USD MILLION)105
TABLE 73ASIA PACIFIC: VETERINARY VACCINE ADJUVANTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)106
11VACCINE ADJUVANTS MARKET, BY REGION107
11.1INTRODUCTION108
TABLE 74VACCINE ADJUVANTS MARKET, BY REGION, 2020–2027 (USD MILLION)108
11.2NORTH AMERICA108
FIGURE 27NORTH AMERICA: VACCINE ADJUVANTS MARKET SNAPSHOT109
TABLE 75NORTH AMERICA: VACCINE ADJUVANTS MARKET, BY COUNTRY,
2020–2027 (USD MILLION)110
TABLE 76NORTH AMERICA: VACCINE ADJUVANTS MARKET, BY PRODUCT,
2020–2027 (USD MILLION)110
TABLE 77NORTH AMERICA: VACCINE ADJUVANTS MARKET,
BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)110
TABLE 78NORTH AMERICA: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE,
2020–2027 (USD MILLION)111
TABLE 79NORTH AMERICA: VACCINE ADJUVANTS MARKET, BY APPLICATION,
2020–2027 (USD MILLION)111
TABLE 80NORTH AMERICA: VACCINE ADJUVANTS MARKET, BY APPLICATION CATEGORY, 2020–2027 (USD MILLION)111

11.2.1US112
11.2.1.1US dominates North American vaccine adjuvants market112
TABLE 81US: VACCINE ADJUVANTS MARKET, BY PRODUCT,
2020–2027 (USD MILLION)113
TABLE 82US: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION,
2020–2027 (USD MILLION)113
TABLE 83US: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE,
2020–2027 (USD MILLION)113
TABLE 84US: VACCINE ADJUVANTS MARKET, BY APPLICATION,
2020–2027 (USD MILLION)114
TABLE 85US: VACCINE ADJUVANTS MARKET, BY APPLICATION CATEGORY,
2020–2027 (USD MILLION)114
11.2.2CANADA114
11.2.2.1Increasing government funding for vaccine research to drive market114
TABLE 86CANADA: VACCINE ADJUVANTS MARKET, BY PRODUCT,
2020–2027 (USD MILLION)115
TABLE 87CANADA: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)115
TABLE 88CANADA: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE,
2020–2027 (USD MILLION)115
TABLE 89CANADA: VACCINE ADJUVANTS MARKET, BY APPLICATION,
2020–2027 (USD MILLION)116
TABLE 90CANADA: VACCINE ADJUVANTS MARKET, BY APPLICATION CATEGORY,
2020–2027 (USD MILLION)116
11.3EUROPE117
TABLE 91EUROPE: VACCINE ADJUVANTS MARKET, BY COUNTRY,
2020–2027 (USD MILLION)117
TABLE 92EUROPE: VACCINE ADJUVANTS MARKET, BY PRODUCT,
2020–2027 (USD MILLION)117
TABLE 93EUROPE: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)118
TABLE 94EUROPE: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE,
2020–2027 (USD MILLION)118
TABLE 95EUROPE: VACCINE ADJUVANTS MARKET, BY APPLICATION,
2020–2027 (USD MILLION)118
TABLE 96EUROPE: VACCINE ADJUVANTS MARKET, BY APPLICATION CATEGORY,
2020–2027 (USD MILLION)119
11.3.1GERMANY119
11.3.1.1Growing funding from government organizations to drive market119
TABLE 97GERMANY: VACCINE ADJUVANTS MARKET, BY PRODUCT,
2020–2027 (USD MILLION)120
TABLE 98GERMANY: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)120
TABLE 99GERMANY: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE,
2020–2027 (USD MILLION)120
TABLE 100GERMANY: VACCINE ADJUVANTS MARKET, BY APPLICATION,
2020–2027 (USD MILLION)121
TABLE 101GERMANY: VACCINE ADJUVANTS MARKET, BY APPLICATION CATEGORY, 2020–2027 (USD MILLION)121
11.3.2UK121
11.3.2.1Rising investments in vaccine development to boost market growth121
TABLE 102UK: VACCINE ADJUVANTS MARKET, BY PRODUCT,
2020–2027 (USD MILLION)122
TABLE 103UK: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION,
2020–2027 (USD MILLION)122
TABLE 104UK: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE,
2020–2027 (USD MILLION)123
TABLE 105UK: VACCINE ADJUVANTS MARKET, BY APPLICATION,
2020–2027 (USD MILLION)123
TABLE 106UK: VACCINE ADJUVANTS MARKET, BY APPLICATION CATEGORY,
2020–2027 (USD MILLION)123
11.3.3FRANCE124
11.3.3.1Focus on new vaccine development to drive market124
TABLE 107FRANCE: VACCINE ADJUVANTS MARKET, BY PRODUCT,
2020–2027 (USD MILLION)124
TABLE 108FRANCE: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)125
TABLE 109FRANCE: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE,
2020–2027 (USD MILLION)125
TABLE 110FRANCE: VACCINE ADJUVANTS MARKET, BY APPLICATION,
2020–2027 (USD MILLION)125
TABLE 111FRANCE: VACCINE ADJUVANTS MARKET, BY APPLICATION CATEGORY,
2020–2027 (USD MILLION)126
11.3.4ITALY126
11.3.4.1Increase in R&D for vaccines and government initiatives—key factors driving market126
TABLE 112ITALY: VACCINE ADJUVANTS MARKET, BY PRODUCT,
2020–2027 (USD MILLION)126
TABLE 113ITALY: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION,
2020–2027 (USD MILLION)127
TABLE 114ITALY: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE,
2020–2027 (USD MILLION)127
TABLE 115ITALY: VACCINE ADJUVANTS MARKET, BY APPLICATION,
2020–2027 (USD MILLION)127
TABLE 116ITALY: VACCINE ADJUVANTS MARKET, BY APPLICATION CATEGORY,
2020–2027 (USD MILLION)128
11.3.5SPAIN128
11.3.5.1Increasing investments in vaccine development by government and private organizations to drive market128
TABLE 117SPAIN: VACCINE ADJUVANTS MARKET, BY PRODUCT,
2020–2027 (USD MILLION)129
TABLE 118SPAIN: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)129
TABLE 119SPAIN: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE,
2020–2027 (USD MILLION)129
TABLE 120SPAIN: VACCINE ADJUVANTS MARKET, BY APPLICATION,
2020–2027 (USD MILLION)130
TABLE 121SPAIN: VACCINE ADJUVANTS MARKET, BY APPLICATION CATEGORY,
2020–2027 (USD MILLION)130
11.3.6REST OF EUROPE130
TABLE 122REST OF EUROPE: VACCINE ADJUVANTS MARKET, BY PRODUCT,
2020–2027 (USD MILLION)131
TABLE 123REST OF EUROPE: VACCINE ADJUVANTS MARKET,
BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)131
TABLE 124REST OF EUROPE: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE,
2020–2027 (USD MILLION)131
TABLE 125REST OF EUROPE: VACCINE ADJUVANTS MARKET, BY APPLICATION,
2020–2027 (USD MILLION)132
TABLE 126REST OF EUROPE: VACCINE ADJUVANTS MARKET, BY APPLICATION CATEGORY, 2020–2027 (USD MILLION)132
11.4ASIA PACIFIC132
FIGURE 28ASIA PACIFIC: VACCINE ADJUVANTS MARKET SNAPSHOT133
TABLE 127ASIA PACIFIC: VACCINE ADJUVANTS MARKET, BY COUNTRY,
2020–2027 (USD MILLION)134
TABLE 128ASIA PACIFIC: VACCINE ADJUVANTS MARKET, BY PRODUCT,
2020–2027 (USD MILLION)134
TABLE 129ASIA PACIFIC: VACCINE ADJUVANTS MARKET,
BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)134
TABLE 130ASIA PACIFIC: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE,
2020–2027 (USD MILLION)135
TABLE 131ASIA PACIFIC: VACCINE ADJUVANTS MARKET, BY APPLICATION,
2020–2027 (USD MILLION)135
TABLE 132ASIA PACIFIC: VACCINE ADJUVANTS MARKET, BY APPLICATION CATEGORY, 2020–2027 (USD MILLION)135
11.4.1CHINA136
11.4.1.1Government support and strategic initiatives by key players to strengthen biotechnology sector136
TABLE 133CHINA: VACCINE ADJUVANTS MARKET, BY PRODUCT,
2020–2027 (USD MILLION)136
TABLE 134CHINA: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)137
TABLE 135CHINA: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE,
2020–2027 (USD MILLION)137
TABLE 136CHINA: VACCINE ADJUVANTS MARKET, BY APPLICATION,
2020–2027 (USD MILLION)137
TABLE 137CHINA: VACCINE ADJUVANTS MARKET, BY APPLICATION CATEGORY,
2020–2027 (USD MILLION)138
11.4.2JAPAN138
11.4.2.1Government initiatives for vaccines to boost market138
TABLE 138JAPAN: VACCINE ADJUVANTS MARKET, BY PRODUCT,
2020–2027 (USD MILLION)138
TABLE 139JAPAN: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)139
TABLE 140JAPAN: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE,
2020–2027 (USD MILLION)139
TABLE 141JAPAN: VACCINE ADJUVANTS MARKET, BY APPLICATION,
2020–2027 (USD MILLION)139
TABLE 142JAPAN: VACCINE ADJUVANTS MARKET, BY APPLICATION CATEGORY,
2020–2027 (USD MILLION)140
11.4.3INDIA140
11.4.3.1Growth of the biotechnology sector and development of new vaccines to drive market140
TABLE 143INDIA: VACCINE ADJUVANTS MARKET, BY PRODUCT,
2020–2027 (USD MILLION)140
TABLE 144INDIA: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)141
TABLE 145INDIA: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE,
2020–2027 (USD MILLION)141
TABLE 146INDIA: VACCINE ADJUVANTS MARKET, BY APPLICATION,
2020–2027 (USD MILLION)141
TABLE 147INDIA: VACCINE ADJUVANTS MARKET, BY APPLICATION CATEGORY,
2020–2027 (USD MILLION)142
11.4.4REST OF ASIA PACIFIC142
TABLE 148REST OF ASIA PACIFIC: VACCINE ADJUVANTS MARKET, BY PRODUCT,
2020–2027 (USD MILLION)142
TABLE 149REST OF ASIA PACIFIC: VACCINE ADJUVANTS MARKET,
BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)143
TABLE 150REST OF ASIA PACIFIC: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)143
TABLE 151REST OF ASIA PACIFIC: VACCINE ADJUVANTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)143
TABLE 152REST OF ASIA PACIFIC: VACCINE ADJUVANTS MARKET, BY APPLICATION CATEGORY, 2020–2027 (USD MILLION)144
11.5LATIN AMERICA144
11.5.1SURGE IN PHARMACEUTICAL AND BIOTECHNOLOGY RESEARCH—
KEY FACTOR DRIVING MARKET144
TABLE 153LATIN AMERICA: VACCINE ADJUVANTS MARKET, BY PRODUCT,
2020–2027 (USD MILLION)144
TABLE 154LATIN AMERICA: VACCINE ADJUVANTS MARKET,
BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)145
TABLE 155LATIN AMERICA: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE,
2020–2027 (USD MILLION)145
TABLE 156LATIN AMERICA: VACCINE ADJUVANTS MARKET, BY APPLICATION,
2020–2027 (USD MILLION)145
TABLE 157LATIN AMERICA: VACCINE ADJUVANTS MARKET, BY APPLICATION CATEGORY, 2020–2027 (USD MILLION)146
11.6MIDDLE EAST AND AFRICA146
11.6.1INCREASING FUNDING AND GRANTS FOR VACCINE DEVELOPMENT TO DRIVE MARKET146
TABLE 158MIDDLE EAST AND AFRICA: VACCINE ADJUVANTS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)146
TABLE 159MIDDLE EAST AND AFRICA: VACCINE ADJUVANTS MARKET,
BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)147
TABLE 160MIDDLE EAST AND AFRICA: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)147
TABLE 161MIDDLE EAST AND AFRICA: VACCINE ADJUVANTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)147
TABLE 162MIDDLE EAST AND AFRICA: VACCINE ADJUVANTS MARKET, BY APPLICATION CATEGORY, 2020–2027 (USD MILLION)148
12COMPETITIVE LANDSCAPE149
12.1INTRODUCTION149
12.2RIGHT-TO-WIN APPROACHES ADOPTED BY KEY PLAYERS150
FIGURE 29VACCINE ADJUVANTS MARKET: STRATEGIES ADOPTED150
12.3MARKET SHARE ANALYSIS151
FIGURE 30VACCINE ADJUVANTS MARKET SHARE ANALYSIS, BY KEY PLAYER (2021)151
TABLE 163VACCINE ADJUVANTS MARKET: DEGREE OF COMPETITION151
12.4REVENUE ANALYSIS152
FIGURE 31REVENUE ANALYSIS FOR KEY COMPANIES (2019–2021)152
12.5COMPANY EVALUATION QUADRANT153
12.5.1STARS153
12.5.2EMERGING LEADERS153
12.5.3PERVASIVE PLAYERS153
12.5.4PARTICIPANTS153
FIGURE 32VACCINE ADJUVANTS MARKET: COMPANY EVALUATION MATRIX, 2021154
12.6COMPETITIVE BENCHMARKING OF TOP 25 PLAYERS155
12.6.1COMPANY FOOTPRINT (25 COMPANIES)155
TABLE 164PRODUCT AND REGIONAL FOOTPRINT ANALYSIS OF KEY PLAYERS IN VACCINE ADJUVANTS MARKET155
12.6.2COMPANY PRODUCT FOOTPRINT (25 COMPANIES)156
TABLE 165PRODUCT FOOTPRINT ANALYSIS OF KEY PLAYERS IN VACCINE ADJUVANTS MARKET156
12.6.3COMPANY REGIONAL FOOTPRINT (25 COMPANIES)157
TABLE 166REGIONAL FOOTPRINT ANALYSIS OF KEY PLAYERS IN VACCINE ADJUVANTS MARKET157
12.7COMPANY EVALUATION QUADRANT FOR STARTUPS/SMES158
12.7.1PROGRESSIVE COMPANIES158
12.7.2STARTING BLOCKS158
12.7.3RESPONSIVE COMPANIES158
12.7.4DYNAMIC COMPANIES158
FIGURE 33VACCINE ADJUVANTS MARKET: COMPANY EVALUATION MATRIX FOR STARTUPS/SMES, 2021159
12.8COMPETITIVE BENCHMARKING OF STARTUP/SME PLAYERS160
TABLE 167DETAILED LIST OF KEY STARTUP/SMES160
TABLE 168COMPETITIVE BENCHMARKING OF KEY PLAYERS (STARTUPS/SMES)161
12.9COMPETITIVE SCENARIO AND TRENDS161
12.9.1PRODUCT LAUNCHES161
TABLE 169KEY PRODUCT LAUNCHES, JANUARY 2019–JULY 2022161
12.9.2DEALS162
TABLE 170KEY DEALS, JANUARY 2019–JULY 2022162
12.9.3OTHER KEY DEVELOPMENTS163
TABLE 171OTHER KEY DEVELOPMENTS, JANUARY 2019–JULY 2022163
13COMPANY PROFILES164
13.1KEY PLAYERS164
(Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments)*
13.1.1GSK PLC164
TABLE 172GSK PLC: BUSINESS OVERVIEW164
FIGURE 34GSK PLC: COMPANY SNAPSHOT (2021)165
13.1.2DYNAVAX TECHNOLOGIES169
TABLE 173DYNAVAX TECHNOLOGIES: BUSINESS OVERVIEW169
FIGURE 35DYNAVAX TECHNOLOGIES: COMPANY SNAPSHOT (2021)169
13.1.3NOVAVAX173
TABLE 174NOVAVAX: BUSINESS OVERVIEW173
FIGURE 36NOVAVAX: COMPANY SNAPSHOT (2021)173
13.1.4AGENUS INC.176
TABLE 175AGENUS INC.: BUSINESS OVERVIEW176
FIGURE 37AGENUS INC.: COMPANY SNAPSHOT (2021)176
13.1.5CRODA INTERNATIONAL PLC178
TABLE 176CRODA INTERNATIONAL PLC: BUSINESS OVERVIEW178
FIGURE 38CRODA INTERNATIONAL PLC: COMPANY SNAPSHOT (2021)179
13.1.6SEPPIC (SUBSIDIARY OF AIR LIQUIDE GROUP)181
TABLE 177AIR LIQUIDE GROUP: BUSINESS OVERVIEW181
FIGURE 39AIR LIQUIDE: COMPANY SNAPSHOT (2021)182
13.1.7PHIBRO ANIMAL HEALTH CORPORATION184
TABLE 178PHIBRO ANIMAL HEALTH CORPORATION: BUSINESS OVERVIEW184
FIGURE 40PHIBRO ANIMAL HEALTH CORPORATION: COMPANY SNAPSHOT (2020)185
13.1.8SPI PHARMA (SUBSIDIARY OF ASSOCIATED BRITISH FOODS PLC)186
TABLE 179ASSOCIATED BRITISH FOODS PLC: BUSINESS OVERVIEW186
FIGURE 41ASSOCIATED BRITISH FOODS PLC: COMPANY SNAPSHOT (2021)187
13.1.9CSL LIMITED188
TABLE 180CSL LIMITED: BUSINESS OVERVIEW188
FIGURE 42CSL LIMITED: COMPANY SNAPSHOT (2021)189
13.1.10MERCK KGAA191
TABLE 181MERCK KGAA: BUSINESS OVERVIEW191
FIGURE 43MERCK KGAA: COMPANY SNAPSHOT (2021)192
13.1.11OZ BIOSCIENCES193
TABLE 182OZ BIOSCIENCES: BUSINESS OVERVIEW193
13.1.12INVIVOGEN194
TABLE 183INVIVOGEN: BUSINESS OVERVIEW194
13.1.13ALLERGY THERAPEUTICS196
TABLE 184ALLERGY THERAPEUTICS: BUSINESS OVERVIEW196
FIGURE 44ALLERGY THERAPEUTICS: COMPANY SNAPSHOT (2020)196
13.1.14VERTELLUS198
TABLE 185VERTELLUS: BUSINESS OVERVIEW198
13.1.15EUBIOLOGICS CO., LTD.199
TABLE 186EUBIOLOGICS CO., LTD.: BUSINESS OVERVIEW199
13.1.16PACIFIC GENETECH LIMITED200
TABLE 187PACIFIC GENETECH LIMITED: BUSINESS OVERVIEW200
13.1.17HAWAII BIOTECH INC.201
TABLE 188HAWAII BIOTECH INC.: BUSINESS OVERVIEW201
13.1.18RIBOXX GMBH202
TABLE 189RIBOXX GMBH: BUSINESS OVERVIEW202
13.1.19CAPTIVATE PHARMACEUTICALS LLC203
TABLE 190CAPTIVATE PHARMACEUTICALS LLC: BUSINESS OVERVIEW203
13.1.20VAXINE PTY LTD.204
TABLE 191VAXINE PTY LTD.: BUSINESS OVERVIEW204
*Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments might not be captured in case of unlisted companies.
13.2OTHER COMPANIES205
13.2.1CREATIVE DIAGNOSTICS205
13.2.2LITEVAX BV205
13.2.3MUKTA INDUSTRIES206
13.2.4ONCOVIR, INC.206
13.2.5TITERMAX USA, INC.207
14APPENDIX208
14.1DISCUSSION GUIDE208
14.2KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL211
14.3CUSTOMIZATION OPTIONS213
14.4RELATED REPORTS213
14.5AUTHOR DETAILS214

Report Title: Vaccine Adjuvants Market by Product (Particulate, Emulsions, Pathogen, Saponin), Route of Administration (Subcutaneous, Intramuscular), Disease Type (Infectious, Cancer), Application (Research, Commercial) & Application Category - Global Forecast to 2027


Your Details
Valid Invalid number

SELECT A FORMAT

ADD TO CART BUY NOW

Related Report

2023 What's Next for Vietnam Diagnostics Market?--2022 Supplier Shares and Strategies, 2022-2027 Volume and Sales Forecasts for 500 Tests--Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM

2023 What's Next for Vietnam Diagnostics Market?--2022 Supplier Shares and Strategies, 2022-2027 Volume and Sales Forecasts for 500 Tests--Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM

2023 What's Next for Venezuela Diagnostics Market?--2022 Supplier Shares and Strategies, 2022-2027 Volume and Sales Forecasts for 500 Tests--Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM

2023 What's Next for Venezuela Diagnostics Market?--2022 Supplier Shares and Strategies, 2022-2027 Volume and Sales Forecasts for 500 Tests--Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM

2023 What's Next for US Diagnostics Market?--2022 Supplier Shares and Strategies, 2022-2027 Volume and Sales Forecasts for 500 Tests--Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM

2023 What's Next for US Diagnostics Market?--2022 Supplier Shares and Strategies, 2022-2027 Volume and Sales Forecasts for 500 Tests--Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM

2023 What's Next for Uruguay Diagnostics Market?--2022 Supplier Shares and Strategies, 2022-2027 Volume and Sales Forecasts for 500 Tests--Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM

2023 What's Next for Uruguay Diagnostics Market?--2022 Supplier Shares and Strategies, 2022-2027 Volume and Sales Forecasts for 500 Tests--Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM

2023 What's Next for United Arab Emirates Diagnostics Market?--2022 Supplier Shares and Strategies, 2022-2027 Volume and Sales Forecasts for 500 Tests--Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM

2023 What's Next for United Arab Emirates Diagnostics Market?--2022 Supplier Shares and Strategies, 2022-2027 Volume and Sales Forecasts for 500 Tests--Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM

2023 What's Next for Ukraine Diagnostics Market?--2022 Supplier Shares and Strategies, 2022-2027 Volume and Sales Forecasts for 500 Tests--Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM

2023 What's Next for Ukraine Diagnostics Market?--2022 Supplier Shares and Strategies, 2022-2027 Volume and Sales Forecasts for 500 Tests--Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM